These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 39373900)

  • 41. [18F]FDG PET/CT for predicting triple-negative breast cancer outcomes after neoadjuvant chemotherapy with or without pembrolizumab.
    Seban RD; Arnaud E; Loirat D; Cabel L; Cottu P; Djerroudi L; Hescot S; Loap P; Bonneau C; Bidard FC; Huchet V; Jehanno N; Berenbaum A; Champion L; Buvat I
    Eur J Nucl Med Mol Imaging; 2023 Nov; 50(13):4024-4035. PubMed ID: 37606858
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The prognostic value of volume-based parameters using
    Park JS; Lee N; Beom SH; Kim HS; Lee CK; Rha SY; Chung HC; Yun M; Cho A; Jung M
    Gastric Cancer; 2018 Mar; 21(2):213-224. PubMed ID: 28643145
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prognostic Role of 2-[
    Albano D; Dondi F; Mazzoletti A; Bellini P; Rodella C; Bertagna F
    Diagnostics (Basel); 2021 Nov; 11(12):. PubMed ID: 34943426
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Metabolic tumour area: a novel prognostic indicator based on
    Cui S; Xin W; Wang F; Shao X; Shao X; Niu R; Zhang F; Shi Y; Liu B; Gu W; Wang Y
    BMC Cancer; 2024 Jul; 24(1):895. PubMed ID: 39054508
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antibody-drug conjugates in metastatic triple negative breast cancer: a spotlight on sacituzumab govitecan, ladiratuzumab vedotin, and trastuzumab deruxtecan.
    McGuinness JE; Kalinsky K
    Expert Opin Biol Ther; 2021 Jul; 21(7):903-913. PubMed ID: 33089726
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Stratifying triple-negative breast cancer prognosis using 18F-FDG-PET/CT imaging.
    Yue Y; Cui X; Bose S; Audeh W; Zhang X; Fraass B
    Breast Cancer Res Treat; 2015 Oct; 153(3):607-16. PubMed ID: 26346756
    [TBL] [Abstract][Full Text] [Related]  

  • 47. High prognostic value of 18F-FDG PET for metastatic gastroenteropancreatic neuroendocrine tumors: a long-term evaluation.
    Bahri H; Laurence L; Edeline J; Leghzali H; Devillers A; Raoul JL; Cuggia M; Mesbah H; Clement B; Boucher E; Garin E
    J Nucl Med; 2014 Nov; 55(11):1786-90. PubMed ID: 25286923
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical Utility of Pre-Therapeutic [18F]FDG PET/CT Imaging for Predicting Outcomes in Breast Cancer.
    Najid S; Seban RD; Champion L; De Moura A; Sebbag C; Salaün H; Cabel L; Bonneau C
    J Clin Med; 2023 Aug; 12(17):. PubMed ID: 37685551
    [TBL] [Abstract][Full Text] [Related]  

  • 49. 18F-FDG PET/CT metrics-based stratification of large B-cell lymphoma receiving CAR-T cell therapy: immunosuppressive tumor microenvironment as a negative prognostic indicator in patients with high tumor burden.
    Sheng LS; Shen R; Yan ZX; Wang C; Zheng X; Zhang YL; Yang HX; Wu W; Xu PP; Cheng S; Bachy E; Sesques P; Jacquet-Francillon N; Jiang XF; Zhao WL; Wang L
    Biomark Res; 2024 Sep; 12(1):104. PubMed ID: 39272132
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prognostic Impact of Pretreatment 2-[
    Albano D; Dondi F; Mazzoletti A; Bellini P; Giubbini R; Bertagna F
    Medicina (Kaunas); 2021 May; 57(5):. PubMed ID: 34069203
    [No Abstract]   [Full Text] [Related]  

  • 51. The prognostic relationship of 18F-FDG PET/CT metabolic and volumetric parameters in metastatic ALK + NSCLC.
    Agüloğlu N; Aksu A; Unat DS; Akyol M
    Nucl Med Commun; 2022 Dec; 43(12):1217-1224. PubMed ID: 36345766
    [TBL] [Abstract][Full Text] [Related]  

  • 52.
    Liu C; Ma G; Zhang J; Cheng J; Yang Z; Song S
    Ann Nucl Med; 2023 Dec; 37(12):675-684. PubMed ID: 37787851
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Novel Anti-HER2 Antibody-Drug Conjugates Versus T-DM1 for HER2-Positive Metastatic Breast Cancer After Tyrosine Kinase Inhibitors Treatment.
    Ji C; Li F; Yuan Y; Zhang H; Bian L; Zhang S; Wang T; Li J; Jiang Z
    Oncologist; 2023 Oct; 28(10):e859-e866. PubMed ID: 37218076
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non-small cell lung cancer treated with first-line pembrolizumab.
    Dall'Olio FG; Calabrò D; Conci N; Argalia G; Marchese PV; Fabbri F; Fragomeno B; Ricci D; Fanti S; Ambrosini V; Ardizzoni A
    Eur J Cancer; 2021 Jun; 150():99-107. PubMed ID: 33892411
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prognostic Value of Tumor Heterogeneity on 18F-FDG PET/CT in HR+HER2- Metastatic Breast Cancer Patients receiving 500 mg Fulvestrant: a retrospective study.
    Zhao Y; Liu C; Zhang Y; Gong C; Li Y; Xie Y; Wu B; Yang Z; Wang B
    Sci Rep; 2018 Sep; 8(1):14458. PubMed ID: 30262849
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Trastuzumab deruxtecan versus treatment of physician's choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 study.
    Yamashita T; Sohn JH; Tokunaga E; Niikura N; Park YH; Lee KS; Chae YS; Xu B; Wang X; Im SA; Li W; Lu YS; Aguilar CO; Nishijima S; Nishiyama Y; Sugihara M; Modi S; Tsurutani J
    Breast Cancer; 2024 Sep; 31(5):858-868. PubMed ID: 38884900
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Combined morphologic-metabolic biomarkers from [18F]FDG-PET/CT stratify prognostic groups in low-risk NSCLC.
    Deininger K; Raacke JN; Yousefzadeh-Nowshahr E; Kropf-Sanchen C; Muehling B; Beer M; Glatting G; Beer AJ; Thaiss W
    Nuklearmedizin; 2023 Oct; 62(5):284-292. PubMed ID: 37696296
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Early Changes of the Standardized Uptake Values (SUV
    Sirico M; Bernocchi O; Sobhani N; Giudici F; Corona SP; Vernieri C; Nichetti F; Cappelletti MR; Milani M; Strina C; Cervoni V; Barbieri G; Ziglioli N; Dester M; Bianchi GV; De Braud F; Generali D
    Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33182575
    [No Abstract]   [Full Text] [Related]  

  • 59. Metabolic parameters of pretreatment 2-[
    Li C; Dong Y; Pan Y; Han Y; Zhang J; Luan X; Liu J; Xu X; Guan Z; Wang G; Xu B
    Quant Imaging Med Surg; 2024 Jan; 14(1):604-617. PubMed ID: 38223061
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prognostic role of pretreatment 18F-FDG PET/CT in primary brain lymphoma.
    Albano D; Bertoli M; Battistotti M; Rodella C; Statuto M; Giubbini R; Bertagna F
    Ann Nucl Med; 2018 Oct; 32(8):532-541. PubMed ID: 29982990
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.